In a 2-year clinical trial, 78% of people taking AVONEX showed no increase in disability, compared to 65% of those taking a placebo. This means AVONEX demonstrated a reduction in disability progression compared to the placebo group in the studied population.
Key Finding from Study 1:
- AVONEX: 78% of patients showed no increase in disability.
- Placebo: 65% of patients showed no increase in disability.
This result indicates AVONEX's effectiveness in slowing the progression of disability in some individuals with Multiple Sclerosis (MS).
